Edison Investment Research - Morphosys AG (MOR) Update: MOR208 and MOR202 data at ASH

Report

Edison Investment Research

Update: MOR208 and MOR202 data at ASH

At the American Society of Hematology (ASH) annual meeting, compelling early combination data on MOR208 and MOR202 were presented. MOR208 with lenalidomide in previously untreated chronic lymphocytic leukemia (CLL) patients demonstrated a 100% (four/four) response rate in evaluable patients. In the relapsed/refractory CLL population, the combination demonstrated a 43% (3/7) response rate. MOR202 in combination with lenalidomide or pomalidomide demonstrated a 50% (three/six) response rate in relapsed/refractory multiple myeloma (MM) patients.

17/12/2015 8 EN

Underlying

Morphosys AG

See profile

Frankfurt Stock Exchange

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

Vermilion Research

Vermilion Int'l Compass: Global Equity Strategy

Not much has changed over the past week when looking at the MSCI ACWI and S&P 500, with prices generally trending sideways and no material changes in our primary breadth indicators. Therefore, our outlook remains positive given breadth and price action improvements on both the ACWI and S&P 500 relative to mid-April (both developments that we highlighted in the 5/17/18 International Compass). â€¢ Major themes: Opportunities within Health Care and Materials. Price and relative strength trends continue to improve for our international equal-weight Health Care Sector. We recommend adding exposure...

May 23, 2018 May 23, 2018 18 EN

EQUITS GmbH

KapitalerhÃ¶hung fÃ¼r ADS- BÃ¶rsengang in den USA â€“ US-$ 239 Mio. BruttoerlÃ¶s

Unter Führung von Goldman Sachs, J.P. Morgan Securities und Leerink Partners platzierte das Konsortium wie geplant 8,30 Mio. American Depositary Shares ("ADS") - + Greenshoe- zu US$ 25,04/ADS, die 1/4 einer MorphoSys-Stammaktie entsprechen. Dem ADS-Angebot zugrunde liegt eine Kapitalerhöhung in Höhe von 2,075 Mio. neuen MOR-Stammaktien. Die frischen Mittel in Höhe von > € 180 Mio. werden in die eigene F&E und insbesondere die Weiterentwicklung von MOR 208 und seiner möglichen späteren Vermarktung fließen. In den USA ist das Interesse für und die Bewertungen an Biotech-Aktien höher

EUR 40.00

April 24, 2018 April 24, 2018 5 DE

Edison Investment Research

- Termination of coverage

Edison Investment Research is terminating coverage on MorphoSys (MOR). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

October 16, 2017 October 16, 2017 1 EN

UIL - Announcement of 2028 privatisation plans

On 8 October 2024, UIL Limited (UIL) announced plans to take the company private after the redemption of the 2028 zero dividend preference (ZDP) shares. UIL’s board has decided that despite holding a selection of potentially exciting investments, recent disappointing performance has meant that the company no longer has the scale to build up a sufficiently diversified portfolio. Also, given that UIL has a limited free float, there is not enough liquidity in its ordinary shares, and its broad investment mandate is out of favour with investors. Therefore, the company will be taken private and its...

12h / 45m 12h / 45m 1 EN

Sean Conroy

Sean Conroy

OSE Immunotherapeutics - Riding the H124 tailwinds

OSE Immunotherapeutics has reported its results for H124, a standout period for the company’s development pipeline, with the momentum carrying into H224. The first half of the year rewarded the company with partnerships deals with AbbVie and Boehringer Ingelheim (BI), bringing in c €84m and securing the cash runway into 2027. Furthermore, H224 so far has seen the company make significant progress in advancing its internal pipeline, with successful Phase II results for Lusvertikimab in ulcerative colitis (UC) and, more importantly, the launch of the Phase III registrational trial for lead asset...

16h / 35m 16h / 35m 1 EN

Richard Williamson

Richard Williamson

1Spatial - Federal-level win in the US

1Spatial’s momentum in the US has continued, with the company securing a $1.4m deal with the United States Forest Service (USFS). This is a new Federal government-level deal for the business, building on the momentum 1Spatial has been reporting at state level, where it now has contracts or framework agreements with 21 states (up from 18 at the FY24 year-end).

17h / 47m 17h / 47m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Update: MOR208 and MOR202 data at ASH

Vermilion Int'l Compass: Global Equity Strategy

KapitalerhÃ¶hung fÃ¼r ADS- BÃ¶rsengang in den USA â€“ US-$ 239 Mio. BruttoerlÃ¶s

- Termination of coverage

UIL - Announcement of 2028 privatisation plans

OSE Immunotherapeutics - Riding the H124 tailwinds

1Spatial - Federal-level win in the US

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe